featured
FOLFIRI Plus Cetuximab or Bevacizumab for Advanced Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
British Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
FOLFIRI Plus Cetuximab or Bevacizumab for Advanced Colorectal Cancer: Final Survival and Per-Protocol Analysis of FIRE-3, A Randomised Clinical Trial
Br. J. Cancer 2020 Nov 06;[EPub Ahead of Print], V Heinemann, LF von Weikersthal, T Decker, A Kiani, F Kaiser, SE Al-Batran, T Heintges, C Lerchenmüller, C Kahl, G Seipelt, F Kullmann, M Moehler, W Scheithauer, S Held, L Miller-Phillips, DP Modest, A Jung, T Kirchner, S StintzingFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.